



**ASX / MEDIA RELEASE**

## **ResApp Receives R&D Tax Incentive Cash Refund for FY16**

**Brisbane, Australia, 21 August 2017** -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has received a cash refund of \$516,305 from its R&D tax incentive claim for the financial year ending 30 June 2016. The Australian Federal Government's R&D Tax Incentive program provides a cash refund on eligible research and development activities performed by Australian companies.

"We were already well funded to complete our clinical program and execute on our commercialisation strategy and these additional funds reinforce our strong financial position," said Tony Keating, CEO and Managing Director of ResApp.

### **About ResApp Health Limited**

ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has adult and paediatric clinical studies underway at leading US and Australian hospitals with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airways disease, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma, pneumonia and upper respiratory tract infections in adults. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as global aid and humanitarian organisations in the developing world.

For more information on ResApp, visit [www.resapphealth.com.au](http://www.resapphealth.com.au)

**ResApp Health Limited** ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 22, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 E [info@resapphealth.com.au](mailto:info@resapphealth.com.au) W [www.resapphealth.com.au](http://www.resapphealth.com.au)



### **Contacts**

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Executive Director and  
Vice President, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

**ResApp Health Limited** ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 22, 44 St Georges Tce, Perth WA 6000 Australia

**T** +61 8 6211 5099 **E** [info@resapphealth.com.au](mailto:info@resapphealth.com.au) **W** [www.resapphealth.com.au](http://www.resapphealth.com.au)